These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1963059)

  • 1. Phosphodiesterase inhibitors. Its role in heart failure therapy.
    Kohn IJ; Ribeiro LG
    Arq Bras Cardiol; 1990 Jun; 54(6):361-5. PubMed ID: 1963059
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology of positive inotropic phosphodiesterase III inhibitors.
    Honerjäger P
    Eur Heart J; 1989 Aug; 10 Suppl C():25-31. PubMed ID: 2553411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Milrinone: basic and clinical pharmacology and acute and chronic management.
    Shipley JB; Tolman D; Hastillo A; Hess ML
    Am J Med Sci; 1996 Jun; 311(6):286-91. PubMed ID: 8659556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
    Van Tassell BW; Radwanski P; Movsesian M; Munger MA
    Pharmacotherapy; 2008 Dec; 28(12):1523-30. PubMed ID: 19025433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review: therapeutic concepts of congestive heart failure.
    Haustein KO
    Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):273-81. PubMed ID: 1974888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of chronic heart failure with positive inotropic drugs].
    Erdmann E
    Internist (Berl); 1986 May; 27(5):298-305. PubMed ID: 3015821
    [No Abstract]   [Full Text] [Related]  

  • 7. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
    Gold J; Cullinane S; Chen J; Seo S; Oz MC; Oliver JA; Landry DW
    Am J Cardiol; 2000 Feb; 85(4):506-8, A11. PubMed ID: 10728962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new inotropic phosphodiesterase inhibitors.
    el Allaf D; D'Orio V; Carlier J
    Arch Int Physiol Biochim; 1984 Nov; 92(4):S69-79. PubMed ID: 6085243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
    Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W
    Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of bipyridine phosphodiesterase III inhibitors.
    Honerjäger P
    Am Heart J; 1991 Jun; 121(6 Pt 2):1939-44. PubMed ID: 1852089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous milrinone: therapeutic responses in heart failure.
    Braunwald E
    Am Heart J; 1991 Jun; 121(6 Pt 2):1937-8. PubMed ID: 2035423
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
    Packer M
    Am J Cardiol; 1989 Jan; 63(2):41A-45A. PubMed ID: 2642629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation.
    Skoyles JR; Sherry KM; Price C
    J Cardiothorac Vasc Anesth; 1992 Apr; 6(2):222-5. PubMed ID: 1568013
    [No Abstract]   [Full Text] [Related]  

  • 14. Positive inotropic/vasodilator agents.
    Colucci WS
    Cardiol Clin; 1989 Feb; 7(1):131-44. PubMed ID: 2565161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of chronic heart failure.
    Poole-Wilson PA; Lindsay D
    BMJ; 1992 Apr; 304(6834):1069-70. PubMed ID: 1586817
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mechanisms and clinical profile of inotropic action of medicines for heart failure].
    Yazaki Y
    Kokyu To Junkan; 1989 Dec; 37(12):1271-7. PubMed ID: 2694254
    [No Abstract]   [Full Text] [Related]  

  • 17. Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.
    Straznicka M; Leone RJ; Scholz PM; Weiss HR
    J Surg Res; 1998 Apr; 76(1):61-6. PubMed ID: 9695741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current inotropic substances].
    Schmitz W
    Schweiz Med Wochenschr; 1988 Apr; 118(17):612-6. PubMed ID: 2837823
    [No Abstract]   [Full Text] [Related]  

  • 19. [Milrinone decreases the positive inotropic response of heart muscle to izadrin].
    Bardamova IB; Afanas'ev SA
    Eksp Klin Farmakol; 1994; 57(4):29-31. PubMed ID: 7950778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotropic drugs for treatment of the failing heart.
    Maskin CS; Le Jemtel TH; Sonnenblick EH
    Cardiovasc Clin; 1984; 14(3):1-17. PubMed ID: 6327040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.